Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer

Proteomics

Volumn 9, Issue 2, 2009, Pages 287-298

  Makridakis, Manousos ^a   Gagos, Sarantis ^a   Petrolekas, Andreas ^b   Roubelakis, Maria G ^a   Bitsika, Vasiliki ^a   Stravodimos, Konstantinos ^b   Pavlakis, Kitty ^b   Anagnou, Nicholas P ^a   Coleman, Jonathan ^c   Vlahou, Antonia ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

2 DE; Cytogenetic analysis; Metastatic variant; Proteomics; T24 cell line

Indexed keywords

CATHEPSIN D; CYTOSKELETON PROTEIN; PROTEASOME; PROTEINASE; PROTEOME;

ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL CULTURE; CANCER TISSUE; CELL LYSATE; CELL MIGRATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; CYTOSKELETON; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KARYOTYPE; LYSOSOME; MITOCHONDRION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEOMICS;

ANIMALS; CATHEPSIN D; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; CHROMOSOME ABERRATIONS; CHROMOSOME PAINTING; CYTOGENETIC ANALYSIS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; PROTEOMICS; STATISTICS, NONPARAMETRIC; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

MUS;

EID: 60349106148     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800121     Document Type: Article

References (41)

1. Dinney, C. P., McConkey, D. J., Millikan, R. E., Wu, X. et al., Focus on bladder cancer. CancerCell 2004, 6, 111-116.
2. Hartge, P., Harvey, E. B., Linehan, W. M., Silverman, D. T. et al., Unexplained Excess Risk of Bladder Cancer in Men. J. Natl. Cancer Inst. 1990, 82, 1636-1640.
3. Sylvester, R. J., Natural history, recurrence, and progression in superficial bladder cancer. Sci. World J. 2006, 6, 2617-2625.
4. Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S. et al., Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J. Clin. Oncol. 2001, 19, 666-675.
5. Habuchi, T., Marberger, M., Droller, M. J., Hemstreet, G. P. lllrd et al., Prognostic markers for bladder cancer: International consensus panel on bladder tumor markers. Urology 2005, 66, 64-74.
6. Lokeshwar, V. B., Habuchi, T., Grossman, H. B., Murphy, W. M. et al., Bladder tumor markers beyond cytology: International consensus panel on bladder tumor markers. Urology 2005, 66, 35-63.
7. Nielsen, M. E., Schaeffer, E. M., Veltri, R. W., Schoenberg, M. P., Getzenberg, R. H., Urinary markers in the detection of bladder cancer: What's new? Curr. Opin. Urol. 2006, 16, 350-355.
8. Crallan, R. A., Georgopoulos, N. T., Southgate J., Experimental models of human bladder carcinogenesis. Carcinogenesis 2006, 27, 374-381.
9. Theodorescu, D., Cornil, I., Fernandez, B. J., Kerbel, R. S., Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc. Natl. Acad. Sci. USA 1990, 87, 9047-9051.
10. Nicholson, B. E., Frierson, H. F., Conaway, M. R., Seraj, J. M. et al., Profiling the evolution of human metastatic bladder cancer. Cancer Res. 2004, 4, 7813-7821.
11. Gildea, J. J., Golden, W. L., Harding, M. A., Theodorescu, D., Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 2000, 27, 252-263.
12. Langen, H., Röder, D., Juranville, J. F., Fountoulakis, M., Effect of protein application mode and acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis. Electrophoresis 1997, 18, 2085-2090.
13. Roubelakis, M. G., Pappa, K. I., Bitsika, V., Zagoura, D. et al., Isolation, phenotypic, molecular and proteomic characterization of human mesenchymal stem cells (MSCs) derived from amniotic fluid: comparison to bone marrow MSCs. Stem Cells Dev. 2007, 16, 931-952.
14. Lopez-Beltran, A., Montironi, R., Non-invasive urothelial neoplasms: According to the most recent WHO classification. Eur. Urol. 2004, 46, 170-176.
15. Sobin, D. H., Wittekind, C. H., TNM Classification of Malignant Tumours, 6th edition, Wiley-Liss, New-York 2002, pp. 199-202.
16. Kerbel, R. S., Cornil, I., Theodorescu, D., Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis. Cancer Metastasis Rev. 1991, 10, 201-215.
17. Harding, M. A., Arden, K. C., Gildea, J. W., Gildea, J. J. et al., Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res. 2002, 62, 6981-6989.
18. Vogelstein, B., Kinzler, K. W., Cancer genes and the pathways they control. Nat. Med. 2004, 10, 789-799.
19. Gagos, S., Irminger-Finger, I., Chromosome instability in neoplasia: Chaotic roots to continuous growth. Int. J. Biochem. Cell Biol. 2005, 37, 1014-1033.
20. Cahill, D. P., Kinzler, K. W., Vogelstein, B., Lengauer, C., Genetic instability and Darwinian selection in tumors. Trends Cell Biol. 1999, 9, 57-60.
21. Rajagopalan, H., Jallepalli, P. V., Rago, C., Velculescu, V. E. et al., Inactivation of hCDC4 can cause chromosomal instability. Nature 2004, 428, 77-81.
22. Williams, S. V., Adams, J., Coulter, J., Summersgill, B. M. et al., Assessment by M-Fish of caryotypic complexity and cytogenetic evolution in bladder cancer in vitro. Genes Chromosomes Cancer 2005, 43, 315-328.
23. Sengelov, L., Christensen, M., von der Maase, H. D., Horn, T. et al., Loss of heterozygosity at 1p, 8p, 10p, 13q, and 17p in advanced urothelial cancer and lack of relation to chemotherapy response and outcome. Cancer Genet Cytogenet. 2000, 723, 109-113.
24. Bohm, M., Wieland, I., Schmidt, C., Rubben, H., Allhoff, E. P., Loss of heterozygosity on chromosome 5p13-12 predicts adverse prognosis in advanced bladder cancer independent of tumor stage and grade. J. Urol. 2002, 768, 2655-2658.
25. Myllyharju, J., Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003, 22, 15-24.
26. Liang, P., MacRae, T. H., Molecular chaperones and the cytoskeleton. J. Cell Sci. 1997, 770, 1431-1440.
27. Mishra, S., Murphy, L. C., Murphy, L. J., The Prohibitins: Emerging roles in diverse functions. J. Cell. Mol. Med. 2006, 70, 353-363.
28. Peng, X., Mehta, R., Wang, S., Chellappan, S., Mehta, R. G., Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res. 2006, 66,7361-7369.
29. Ciechanover, A., Intracellular protein degradation: From a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Exp. Biol. Med. 2006, 237, 1197-1211.
30. Gontero, P., Banisadr, S., Frea, B., Brausi, M., Metastasis markers in bladder cancer: A review of the literature and clinical considerations. Eur. Urol. 2004, 46, 296-311.
31. Lipponen, P. K., Expression of cathepsin D in transitional cell bladder tumours. J. Pathol. 1996, 778, 59-64.
32. Leto, G, Tumminello, F. M, Crescimanno, M, Flandina, C, Gebbia, N., Cathepsin D expression levels in non-gynecological solid tumors: Clinical and therapeutic implications. Clin. Exp. Metastas. 2004, 21, 91-106.
33. Gontero, P., Banisadr, S., Frea, B., Brausi, M., Metastasis markers in bladder cancer: A review of the literature and clinical considerations. Eur. Urol. 2004, 46, 296-311.
34. Tokyol, C., Koken, T., Demirbas, M., Dilek, F. H. et al., Expression of cathepsin D in bladder carcinoma: Correlation with pathological features and serum cystatin C levels. Tumor 2006, 92, 230-235.
35. Ioachim, E., Charchanti, A., Stavropoulos, N., Athanassiou, E. et al., Expression ofcathepsin D in urothelial carcinoma of the urinary bladder: An immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. Anticancer Res. 2002, 22, 3383-3388.
36. Ozer, E., Mungan, M. U., Tuna, B., Kazimoglu, H. et al., Prognostic significance of angiogenesis and immunoreactivity of cathepsin D and type IV collagen in high-grade stage T1 primary bladder cancer. Urology 1999, 54, 50-55.
37. Iizumi, T., Iiyama, T., Tanaka, W., Okada, E. et al., Immunohistochemical studies of proliferating cell nuclear antigen and cathepsin D in transitional cell carcinoma of the urinary bladder. Urol. Int. 1997, 59, 81-87.
38. Dickinson, A. J., Fox, S. B., Newcomb, P. V., Persad, R. A. et al., An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas. J. Urol. 1995, 754, 237-241.
39. Lashinger, L. M., Zhu, K., Williams, S. A., Shrader, M. et al., Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res. 2005, 65, 4902-4908.
40. Rajkumar, S. V., Richardson, P. G., Hideshima, T., Anderson, K. C., Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 2005, 23, 630-639.
41. Liang, G., Gonzales, F. A., Jones, P. A., Orntoft, T. F., Thykjaer, T., Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′ytidine. Cancer Res. 2002, 62, 61-966.